- QMRO Home
- Barts Cancer Institute
- Centre for Haemato-Oncology
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Browse
Administrators only